How will you approach drug sequencing in patients with PMR given the SAPHYR data?
Will you initiate sarilumab as a first steroid sparing agent or will you still pursue a DMARD such as methotrexate before initiating sarilumab? To what extent do you think other IL-6 inhibitors will play a role?
Community PollStarted
When will you use sarilumab in patients with PMR?
63 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Rheumatology · Harvard Medical School- MGH
Answered on
The SAPHYR study enrolled patients with PMR who relapsed while tapering prednisone at daily doses equal to or greater than 7.5 mg. One group of patients received sarilumab 200 mg every 2 weeks along with a 14-week prednisone taper and another group of patients received a placebo along with a 52-week...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Rheumatology · University of Pittsburgh School of Medicine
Answered on · Updated on
This is a great question and one where we need more data to guide clinical practice. As with any new therapy, there will be a slow uptake in practice and we will need to learn more about the use of IL-6 inhibitors in a real-world setting. To date, IL-6 inhibitors are only being used in a minority of...
Join for free or sign in to see the full answer